- Global Pharma News & Resources

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022


NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Commercial Day presentation for the investment community to provide an update on its recently launched product, IGALMI™ (dexmedetomidine) sublingual film, on Tuesday, October 18, 2022 beginning at 11:00 a.m. Eastern Time.


Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will be joined by healthcare experts to discuss clinical insights, treatment perspectives, market opportunities, and launch progress. IGALMI was approved by the U.S. Food and Drug Administration in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.1


Participating healthcare experts will include and discuss:


  • Dr. Sheldon Preskorn, M.D.: The Mechanism of Agitation 

    Dr. Sheldon Preskorn is President and CEO, World-Wide Clinical Psychopharmacology Consultation. He has been principal investigator on more than 250 clinical trials, including drug-development work that has spanned all phases of psychiatric drug development from preclinical research through registration studies, including all antidepressants and antipsychotics marketed in the U.S. over a 25-year period. He also has extensive experience with the drug-registration process, having worked on 16 successful New Drug Applications, including 8 of the 12 antidepressants marketed in the U.S. over a 25-year period and the only implantable device approved for treatment of a psychiatric illness. His clinical and administrative experience includes serving as supervising physician for an acute psychosis ward, chief of psychiatry for a university-affiliated Veterans Administration Medical Center, and supervisor of a residency teaching clinic seeing adult psychiatric outpatients with a diverse range of psychiatric disorders.


  • Karen Sands, MSN, APRN-BC, ANP, CCRN, FCCM: The Front Lines of Agitation 

    Karen Sands is an Adult Nurse practitioner at Novant Health Forsyth Medical Center on the Hospitalist service and is currently serving as faculty preceptor for several NP programs including Duke University School of Nursing, University of South Alabama School of Nursing, and Chamberlin University College of Nursing. She has 34 years of nursing experience, with the last 32 years dedicated to the medical and surgical critical care arena and hospital medicine. 
  • Jacob Hanaie, Pharm. D., APh: The Hospital Formulary Process 

    Dr. Jacob Hanaie is an Advanced Practice prescribing pharmacist, Director of Pharmacy, and distinguished Chairman of the Pharmacy and Therapeutics Committee at Kedren Psychiatric Hospital and Community Mental Health Center in Los Angeles. In addition to research and clinical experience in schizophrenia, depression, bipolar, ADHD/ADD, and dependence, Dr. Hanaie’s expertise includes pharmacology, pharmacokinetics, and pharmacodynamics, along with an in-depth understanding of the complex mental health system at federal, state, and county levels.


Investors interested in attending the in-person event should RSVP by contacting Brennan Doyle at To access a live webcast of the Commercial Day presentation and accompanying presentation materials, please visit "News/Events" within the Investors & Media section of the Company’s website beginning 15 minutes prior to the start time of the presentation. A webcast replay will be available on the website following the event.

Editor Details

Last Updated: 05-Oct-2022